Heart Attack


 ODYSSEY

  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.
  • This study investigates whether the investigational drug alirocumab might prevent future cardiovascular events (such as heart attacks or strokes) in patients who have experienced a coronary event within the past 12 months. The study will compare the effect of the drug versus a placebo in preventing heart attack and stroke, when given in addition to the best possible treatment for lowering cholesterol.
  • One of the main risk factors for developing coronary heart disease is high levels of cholesterol in the blood, in particular high levels of a particular type of cholesterol called LDL-cholesterol (bad cholesterol).  Alirocumab SAR236553 is an antibody (a type of protein) that binds a substance called PCSK9. The substance PCSK9 is secreted from the liver into the blood and increases LDL-cholesterol levels in the blood. Therefore, blocking PCSK9 through the use of the study drug can potentially decrease the blood LDL-cholesterol (bad cholesterol) levels in subjects with high blood cholesterol.
  • Principal Investigator: Carl Pepine

 PRESERVATION

  • A Placebo-Controlled, Multicenter, Randomized, Double Blond Trial to Evaluate the Safety and Effectiveness of IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction.
  • This study investigates whether the investigational new device called IK-5001 can help to prevent heart failure in people who have had a heart attack.  IK-5001 is being studied to prevent remodeling and heart failure by supporting the damaged area of the heart muscle, like a cast or splint. This may prevent that area of the damaged heart muscle from dilating, thinning, and weakening. In enrolled patients, IK-5001 (2/3 of those enrolled) or placebo (1/3 of those enrolled, randomly assigned) will be given by injection using a catheter in a procedure very similar to the cardiac catheterization performed to treat a heart attack.
  • Patients who have had a large ST-elevation myocardial infarction (STEMI) and a successful percutaneous coronary intervention with stent placement may be eligible for screening for this study.
  • Principal Investigator: Carl Pepine

Please contact our Clinical Trials Office for information: (352) 273-8933